Last updated on April 2018

Improving the Treatment for Women With Early Stage Cancer of the Uterus


Brief description of study

Currently the standard treatment for early stage endometrial cancer or endometrial hyperplasia with atypia is a total hysterectomy (an operation to remove the uterus) and removal of both ovaries. While highly effective, this surgery carries significant side effects for:

  • young women who still wish to have children and would lose fertility; and
  • women with one or more disorders (or diseases) in addition to the early stage endometrial cancer or endometrial hyperplasia with atypia and/or morbid obesity who are at risk for surgical complications making surgery unsafe.

This study will access a new approach to the treatment of endometrial cancer to spare women of having to undergo major surgery that may be unwanted or unnecessary.

Mirena is approved in Australia for contraception, to treat heavy bleeding, and to prevent thickening of the lining of the uterus (endometrial hyperplasia) during oestrogen replacement therapy (HRT). However it is not approved to treat early stage endometrial cancer or endometrial hyperplasia with atypia. This research project will test to see if Mirena is an effective treatment for early stage endometrial cancer and endometrial hyperplasia with atypia.

Metformin is approved in Australia to treat Diabetes. However it is not approved to treat early stage endometrial cancer or endometrial hyperplasia with atypia. Therefore, it is an experimental treatment for early stage endometrial cancer and endometrial hyperplasia with atypia. This means that it must be tested to see if it is an effective treatment for early stage endometrial cancer and endometrial hyperplasia with atypia.

Weight loss interventions are feasible and safe, and already being implemented by gynaecologic oncologist to make women eligible for surgery. Weight loss of 7% body weight induces a large biological effect (for example reduces incidence of diabetes by 58%, and hypertension by 26%).

Clinical Study Identifier: NCT01686126

Contact Investigators or Research Sites near you

Start Over

Jonathan Carter

Chris O'Brien Lifehouse
Camperdown, Australia
  Connect »

Geoffrey Otton

John Hunter Hospital
New Lambton, Australia
  Connect »

Jim Nicklin

The Wesley Hospital
Auchenflower, Australia
  Connect »

Vanessa L Taylor

Brisbane Private Hospital
Brisbane, Australia
  Connect »

Andreas Obermair

Royal Brisbane and Women's Hospital
Brisbane, Australia
  Connect »

Andreas Obermair

Greenslopes Private Hospital
Greenslopes, Australia
  Connect »

Lewis Perrin

Mater Health Services, Brisbane
South Brisbane, Australia
  Connect »

Lewis Perrin

Mater Private Hospital
South Brisbane, Australia
  Connect »

Marcelo Nascimento

Gold Coast Hospital
Southport, Australia
  Connect »

Andreas Obermair

Townsville Hospital
Townsville, Australia
  Connect »

Marcelo Nascimento

John Flynn Hospital
Tugun, Australia
  Connect »

Vanessa L Taylor

Royal Adelaide Hospital
Adelaide, Australia
  Connect »

John Miller

Queen Elizabeth Hospital
Woodville, Australia
  Connect »

Orla McNally

Royal Women's Hospital
Carlton, Australia
  Connect »

Vanessa L Taylor

Monash Medical Centre
Clayton, Australia
  Connect »

Yee Leung

King Edward Memorial Hospital for Women
Perth, Australia
  Connect »

Stuart Salfinger

St John of God Hospital
Subiaco, Australia
  Connect »

Peter Sykes

Christchurch Women's Hospital
Christchurch, New Zealand
  Connect »

Cecile Bergzoll

Wellington Hospital
Wellington, New Zealand
  Connect »